van Schooten J, van Gils M
Retrovirology. 2018; 15(1):74.
PMID: 30477581
PMC: 6260891.
DOI: 10.1186/s12977-018-0457-7.
Yacoob C, Lange M, Cohen K, Lathia K, Feng J, Glenn J
PLoS Pathog. 2018; 14(6):e1007120.
PMID: 29933399
PMC: 6033445.
DOI: 10.1371/journal.ppat.1007120.
Bricault C, Kovacs J, Badamchi-Zadeh A, McKee K, Shields J, Gunn B
J Virol. 2018; 92(13).
PMID: 29643249
PMC: 6002713.
DOI: 10.1128/JVI.00369-18.
Shahzad-Ul-Hussan S, Sastry M, Lemmin T, Soto C, Loesgen S, Scott D
Chembiochem. 2017; 18(8):764-771.
PMID: 28166380
PMC: 5557091.
DOI: 10.1002/cbic.201600665.
Sastry M, Bewley C, Kwong P
Methods Enzymol. 2015; 565:289-307.
PMID: 26577736
PMC: 6260808.
DOI: 10.1016/bs.mie.2015.09.021.
Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection.
Wu X, Zhang Z, Schramm C, Joyce M, Kwon Y, Zhou T
Cell. 2015; 161(3):470-485.
PMID: 25865483
PMC: 4706178.
DOI: 10.1016/j.cell.2015.03.004.
Specific sequences commonly found in the V3 domain of HIV-1 subtype C isolates affect the overall conformation of native Env and induce a neutralization-resistant phenotype independent of V1/V2 masking.
Salomon A, Krachmarov C, Lai Z, Honnen W, Zingman B, Sarlo J
Virology. 2013; 448:363-74.
PMID: 24314667
PMC: 3913561.
DOI: 10.1016/j.virol.2013.10.007.
Outer domain of HIV-1 gp120: antigenic optimization, structural malleability, and crystal structure with antibody VRC-PG04.
Joyce M, Kanekiyo M, Xu L, Biertumpfel C, Boyington J, Moquin S
J Virol. 2012; 87(4):2294-306.
PMID: 23236069
PMC: 3571475.
DOI: 10.1128/JVI.02717-12.
Elicitation of neutralizing antibodies directed against CD4-induced epitope(s) using a CD4 mimetic cross-linked to a HIV-1 envelope glycoprotein.
Dey A, Burke B, Sun Y, Sirokman K, Nandi A, Hartog K
PLoS One. 2012; 7(1):e30233.
PMID: 22291921
PMC: 3265465.
DOI: 10.1371/journal.pone.0030233.
Binding interactions between soluble HIV envelope glycoproteins and quaternary-structure-specific monoclonal antibodies PG9 and PG16.
Davenport T, Friend D, Ellingson K, Xu H, Caldwell Z, Sellhorn G
J Virol. 2011; 85(14):7095-107.
PMID: 21543501
PMC: 3126577.
DOI: 10.1128/JVI.00411-11.
Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold.
Totrov M, Jiang X, Kong X, Cohen S, Krachmarov C, Salomon A
Virology. 2010; 405(2):513-23.
PMID: 20663531
PMC: 2942080.
DOI: 10.1016/j.virol.2010.06.027.
Alterations in the immunogenic properties of soluble trimeric human immunodeficiency virus type 1 envelope proteins induced by deletion or heterologous substitutions of the V1 loop.
Ching L, Stamatatos L
J Virol. 2010; 84(19):9932-46.
PMID: 20660181
PMC: 2937763.
DOI: 10.1128/JVI.00868-10.
Conserved structural elements in the V3 crown of HIV-1 gp120.
Jiang X, Burke V, Totrov M, Williams C, Cardozo T, Gorny M
Nat Struct Mol Biol. 2010; 17(8):955-61.
PMID: 20622876
DOI: 10.1038/nsmb.1861.
Specificity of the autologous neutralizing antibody response.
Moore P, Gray E, Morris L
Curr Opin HIV AIDS. 2010; 4(5):358-63.
PMID: 20048698
PMC: 3004050.
DOI: 10.1097/COH.0b013e32832ea7e8.
Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection.
Moore P, Ranchobe N, Lambson B, Gray E, Cave E, Abrahams M
PLoS Pathog. 2009; 5(9):e1000598.
PMID: 19763271
PMC: 2742164.
DOI: 10.1371/journal.ppat.1000598.
Different vaccine vectors delivering the same antigen elicit CD8+ T cell responses with distinct clonotype and epitope specificity.
Honda M, Wang R, Kong W, Kanekiyo M, Akahata W, Xu L
J Immunol. 2009; 183(4):2425-34.
PMID: 19620307
PMC: 2858449.
DOI: 10.4049/jimmunol.0900581.
Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination.
Montefiori D, Morris L, Ferrari G, Mascola J
Curr Opin HIV AIDS. 2009; 2(3):169-76.
PMID: 19372883
PMC: 3171201.
DOI: 10.1097/COH.0b013e3280ef691e.
High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination.
Davis K, Gray E, Moore P, Decker J, Salomon A, Montefiori D
Virology. 2009; 387(2):414-26.
PMID: 19298995
PMC: 2792036.
DOI: 10.1016/j.virol.2009.02.022.
Enhanced exposure of the CD4-binding site to neutralizing antibodies by structural design of a membrane-anchored human immunodeficiency virus type 1 gp120 domain.
Wu L, Zhou T, Yang Z, Svehla K, ODell S, Louder M
J Virol. 2009; 83(10):5077-86.
PMID: 19264769
PMC: 2682083.
DOI: 10.1128/JVI.02600-08.
Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.
Binley J, Lybarger E, Crooks E, Seaman M, Gray E, Davis K
J Virol. 2008; 82(23):11651-68.
PMID: 18815292
PMC: 2583680.
DOI: 10.1128/JVI.01762-08.